ENIGMA virtual meeting 2021
October, 5th-7th
I acknowledge that as an ENIGMA member I will have access to unpublished and confidential information and that I will not share this information to anyone else
Use the plus sign (+) to access the slides and presentations per session
Day 1: General Session - Chairs Mandy Spurdle & Maaike Vreeswijk
Welcome, thanks, housekeeping. Revised Terms of Reference for the Steering Committee, and composition of the SC for the next term – Mandy & Maaike (slides – presentation)
Network of interactions with ENIGMA – Mandy (slides – presentation, from 14.06 minutes onwards)
Update – BRCA1/2 Expert Panel, including updated use of ACMG/AMP criteria – Michael Parsons (slides – presentation)
Update – ClinGen Hereditary Breast Ovarian Pancreatic Cancer Variant Curation Expert Panel, with a focus on ATM – Marcy Richardson, Fergus Couch, Lidia Feliudabaló (slides – presentation)
BRCA Exchange, GA4GH-related activities, VCEP interactions, ENIGMA Data Focus Group – Melissa Cline (slides – presentation)
Day 1: Pathology Working Group - Chairs Melissa Southey & Mads Thomassen
RAD51 assay as biomarker for functional HR: Progress update – Sara Gutierrez-Enriquez & Maaike Vreeswijk (slides – presentation)
Mutational signatures BRCAx – Mads Thomassen (slides – presentation)
Foundation Medicine data analysis and opportunities for collaboration – Garrett Frampton (slides – presentation)
Day 2: Analytical Working Group - Chairs David Goldgar & Kyriaki Michailidoua
Results from the Oncoarray BRCA12 case-control LR analysis – Maria Zanti (slides – presentation part 1, presentation part 2)
BRIDGES in silico missense variants analysis – Leila Dorling (slides – presentation)
CARRIERS missense analysis – Fergus Couch (slides)
Simple method to estimate the proportion of pathogenic variants in case-control data –
Paul James (slides –presentation)
Questions for all speakers
An AWG Simulation Study to answer these questions?
Project ideas – Kyriaki and David (slides –presentation)
Day 2: Functional Working Group - Chairs Maaike Vreeswijk & Alvaro Monteiro
Integrating results from different BRCA2 assays – Alvaro Monteiro (slides –presentation)
“Using a case-control approach to estimate risk associated with RING domain unclassified missense substitutions, stratified by comprehensive mammalian 2-hybrid assay” – Sean Tavtigian (slides –presentation – questions)
BRCA2 hypomorphs – Fergus Couch (Alignment BRCA2 HDR data with Prime editing and Mano B, few slides on PALB2) (slides)
Saturation Genome Editing of PALB2 Reveals Functionally Abnormal Missense Variants –
Lea Starita (slides –presentation)
Functional characterization of CHEK2 VUS – Zdenek Kleibl (slides –presentation)
Functional analysis identifies damaging CHEK2 missense variants associated with increased cancer risk- Rick Boonen. Please contact H.van_Attikum@lumc.nl for more information.
Accessing multiplex assay data for variant interpretation using MaveDB – Alan Rubin (slides –presentation)
Day 3: Splicing Working Group - Chairs Logan Walker & Sara Gutiérrez-Enríquez
Project 7 extension: Building gene specific catalogues of alternative non-BRCA transcripts and PVS1 decision trees – Miguel de la Hoya, Vanessa Lau (slides –presentation)
Use of long reads to assess splicing in full length transcripts – Mads Thomassen, Kathleen Claes (slides Mads Thomassen – slides Kathleen Claes – presentation)
Using direct cDNA long read sequencing to identify full BRCA isoforms and splicing defects as well as whole transcriptome disruption in BRCA mutations – Jade Forster (slides –presentation)
RNA-Seq analysis of BRCA1/2 mutation carrier LCLs – Jim Fackenthal (slides –presentation)
BRCA1 IVS18 splicing variants – Joanna Domènech, Orland Diez & Sara Gutiérrez-Enríquez (slides –presentation)
BRCA1 IVS11 study – general overview and update – Michael Parsons (slides –presentation)
Altered regulation of BRCA1 exon 11 splicing is associated with breast cancer risk in carriers of BRCA1 pathogenic variants – Gorka Ruiz de Garibay (slides – presentation)
Splice prediction analysis – Score thresholds, tools, deep intronic variants (ENIGMA EP, ClinGen splicing subgroup, Other groups):
• Determining computational splicing prediction thresholds – George Wiggins (slides)– presentation)
• Splice prediction analysis for deep intronic variants – Sara Gutiérrez-Enríquez (slides – presentation)
BRCA1/2 Splicing Assay Interpretation – Amanda Spurdle (slides –presentation)
CAGI Project – Diana Baralle (slides –presentation)
Other projects and where to next? (slides – presentation)
Day 3: Clinical Working Group - Chairs Arcangela De Nicola & Encarna Gomez-Garcia
Adverts – ongoing projects/new study proposals (slides – presentation)
• Vocabulary Translation Project (VTP) – Arcangela De Nicolo
• Fanconi Anemia – Amanda Spurdle
• BRCA2 R2784Q reduced penetrance – Encarna Gomez-Garcia
• New proposal: CHEK2 and haematological disorders – Encarna Gomez-Garcia
Analysis of deep intronic variants in BRCA1/2 in patients with HBOC and no exonic pathogenic variant detected including large rearrangements – Angela Solano (slides –presentation)
Outcome of breast cancer patients with germline BRCA mutations and new treatment strategies – Banu Arun (slides –presentation)
Identification of markers of response/resistance to PARP inhibitors and platinums in patients with BRCA positive breast cancer (new project proposal) – Banu Arun (slide 14 from 12.55 onwards –presentation)
Suspected clonal hematopoiesis as a natural functional assay of TP53 germline variant pathogenicity – Cristina Fortuno (slides –presentation)
Discussion and Wrap-up (slides –presentation)